Yttrium-90 Microsphere Brachytherapy for Liver Metastases From Uveal Melanoma
- 1 April 2016
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 39 (2) , 189-195
Abstract
Objectives: To report outcomes after yttrium-90 microsphere brachytherapy for unresectable liver metastases from uveal melanoma and to evaluate factors predictive for overall survival (OS) and hepatic progression-free survival (PFS). Methods: A total of 71 patients were consecutively treated with microsphere brachytherapy for unresectable liver metastases from uveal melanoma between 2007 and 2012. Clinical, radiographic, and positron emission tomography–derived, functional tumor parameters were evaluated by log-rank test in univariate analysis and backwards stepwise multivariate Cox proportional hazards regression. OS and hepatic PFS were estimated by Kaplan-Meier analysis. Results: A total of 134 procedures were performed in 71 patients with a median age of 63 years (range, 23 to 91 y). Fifty-eight patients (82%) received microsphere brachytherapy as a salvage therapy. Median hepatic PFS and OS after microsphere brachytherapy were 5.9 months (range, 1.3 to 19.1 mo) and 12.3 months (range, 1.9 to 49.3 mo), respectively. Median OS times after diagnosis of liver metastases was 23.9 months (range, 6.2 to 69.0 mo). In univariate analysis, female sex, pretreatment metabolic tumor volume, and total glycolic activity (TGA) were significantly correlated with hepatic PFS and OS. In multivariate analysis, female sex and TGA retained significance as independent predictors of hepatic PFS and OS. A low pretreatment TGA (P=0.01). Conclusions: Yttrium-90 microsphere brachytherapy provided favorable survival times in patients with unresectable liver metastases from uveal melanoma. Metabolic tumor volume and TGA are predictive functional tumor parameters, which may aid patient selection and risk stratification.Keywords
This publication has 34 references indexed in Scilit:
- Effectiveness of Treatments for Metastatic Uveal MelanomaAmerican Journal of Ophthalmology, 2009
- A First Report of Radioembolization for Hepatic Metastases From Ocular MelanomaCancer Investigation, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Immunoembolization of Malignant Liver Tumors, Including Uveal Melanoma, Using Granulocyte-Macrophage Colony-Stimulating FactorJournal of Clinical Oncology, 2008
- Hepatic Arterial Chemoembolization for Management of Metastatic MelanomaAmerican Journal of Roentgenology, 2008
- Recommendations for Radioembolization of Hepatic Malignancies Using Yttrium-90 Microsphere Brachytherapy: A Consensus Panel Report from the Radioembolization Brachytherapy Oncology ConsortiumInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2007
- Assessment of response to treatment of unresectable liver tumours with 90Y microspheres: Value of FDG PET versus computed tomographyNuclear Medicine Communications, 2007
- 90Y Microsphere (TheraSphere) Treatment for Unresectable Colorectal Cancer Metastases of the Liver: Response to Treatment at Targeted Doses of 135–150 Gy as Measured by [18F]Fluorodeoxyglucose Positron Emission Tomography and Computed Tomographic ImagingJournal of Vascular and Interventional Radiology, 2005
- Variates of Survival in Metastatic Uveal MelanomaJournal of Clinical Oncology, 2005
- Chemoembolization of the hepatic artery with BCNU for metastatic uveal melanoma: results of a phase II studyMelanoma Research, 2005